Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinxin Fertility GroupHKSE:01951 81 Market Cap is HK$5,514 Mil as of Aug. 11, 2026. GuruFocus rates HKSE:01951 with a GF Score™ of 81/100 and a GF Value™ of HK$3.74 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 690 Healthcare Providers & Services companies, Jinxin Fertility Group ranks better than 75.8% on this metric.
Jinxin Fertility Group's quarterly market cap
increased
from Dec. 2024 (HK$7,172 Mil) to Jun. 2025 (HK$8,204 Mil) but then
declined
from Jun. 2025 (HK$8,204 Mil) to Dec. 2025 (HK$6,286 Mil).
Jinxin Fertility Group's annual market cap
declined
from Dec. 2023 (HK$9,115 Mil) to Dec. 2024 (HK$7,172 Mil) and
declined
from Dec. 2024 (HK$7,172 Mil) to Dec. 2025 (HK$6,286 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Jinxin Fertility Group's Enterprise Value for Today is HK$7,832 Mil.
Jinxin Fertility Group (HKSE:01951) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01951 vs HCA, THC, DVA: Market Cap Comparison
For the Medical Care Facilities subindustry, Jinxin Fertility Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinxin Fertility Group Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jinxin Fertility Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Jinxin Fertility Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Jinxin Fertility Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinxin Fertility Group (HKSE:01951) has a Market Cap of HK$5,514 Mil as of Aug. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Jinxin Fertility Group and its competitors. According to the industry distribution chart, Jinxin Fertility Group ranks #167 out of 690 companies in the Healthcare Providers & Services industry, placing it in the top 24.2%.
Is Jinxin Fertility Group's Market Cap too high?
Jinxin Fertility Group's current Market Cap is HK$5,514 Mil. Based on the distribution chart, Jinxin Fertility Group ranks #167 out of 690 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Jinxin Fertility Group has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jinxin Fertility Group's Market Cap compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jinxin Fertility Group ranks #167 out of 690 companies for Market Cap. This places Jinxin Fertility Group in the top 24% of its industry — outperforming the majority of peers. The industry median Market Cap is 106.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 106.59, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Jinxin Fertility Group and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 106.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinxin Fertility Group's current Market Cap is HK$5,514 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinxin Fertility Group stock overvalued right now?
Based on GuruFocus' analysis, Jinxin Fertility Group (HKSE:01951) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.74, compared to a current price of HK$2.16 — trading 42.2% below its estimated fair value. The current Market Cap is HK$5,514 Mil. Jinxin Fertility Group's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Jinxin Fertility Group (HKSE:01951), the current Market Cap is HK$5,514 Mil as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinxin Fertility Group (HKSE:01951) Overvalued in 2026?
Based on GuruFocus' analysis, Jinxin Fertility Group stock appears to be undervalued.
The current stock price of HK$2.16 is trading 42.2% below its estimated GF Value™ of HK$3.74.
GuruFocus considers Jinxin Fertility Group to be Possible Value Trap.
Key valuation signals for HKSE:01951:
Market Cap: HK$5,514 Mil
GF Value™: HK$3.74 vs. price of HK$2.16 (42.2% below fair value)
No single metric tells the full story. See the HKSE:01951 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinxin Fertility Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in providing IVF services in both China and the United States. The firm, through its subsidiary, is engaged in Assisted reproductive services, management services, ambulatory surgery centre facilities services, obstetrics, gynecology & pediatrics medical services, sales of medical consumables and equipment. and ancillary medical services. Geographically, the company generates a majority of its revenue from Greater China, with a small portion of revenue generated from Overseas Business.
81GF Score
Get the complete analysis for HKSE:01951
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01951 has been successfully added to your 
